The Netherlands journal of medicine · 2010
Novel therapies for hypereosinophilic syndromes.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Antoniu S A
Аннотация
BACKGROUND: Conventional therapies (corticosteroids, cytotoxic agents or interferon-a) or newer compounds such imatinib are used specifically in subsets of hypereosinophilic syndromes (HES). However other therapies are still needed in this condition.
OBJECTIVE: To review the novel therapies for HES discussing their advantages and shortcomings.
METHODS AND RESULTS: Preclinical and clinical data on novel tyrosine kinase inhibitors, anti-IL -5 antibodies or anti-CD52 antibodies (alemtuzumab) are analysed. The former might represent appropriate options in case of imatinib resistance; the efficacy of anti-IL-5 monoclonal antibodies therapy is limited by the occurrence of rebound eosinophilia and alemtuzumab might be a promising anti-eosinophil therapy for all HES subsets.
CONCLUSION: Some of the novel therapies might become appropriate therapeutic options for HES.
OBJECTIVE: To review the novel therapies for HES discussing their advantages and shortcomings.
METHODS AND RESULTS: Preclinical and clinical data on novel tyrosine kinase inhibitors, anti-IL -5 antibodies or anti-CD52 antibodies (alemtuzumab) are analysed. The former might represent appropriate options in case of imatinib resistance; the efficacy of anti-IL-5 monoclonal antibodies therapy is limited by the occurrence of rebound eosinophilia and alemtuzumab might be a promising anti-eosinophil therapy for all HES subsets.
CONCLUSION: Some of the novel therapies might become appropriate therapeutic options for HES.
Предметные рубрики MeSH
Adrenal Cortex HormonesAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntigens, CDAntigens, NeoplasmAntineoplastic AgentsBenzamidesBenzenesulfonatesBone Marrow TransplantationCD52 AntigenGlycoproteinsHumansHypereosinophilic SyndromeImatinib MesylateImmunologic FactorsInterferon-alphaInterleukin-5NiacinamidePhenylurea CompoundsPiperazinesProtein Kinase InhibitorsProtein-Tyrosine KinasesPyridinesPyrimidinesSorafenib